Abstract
Objective
The aim of this study was to investigate the efficacy of weekly docetaxel (TXT), cisplatin (DDP) combined with continuous infusion of low dose fluorouracil (FU) on advanced gastric carcinoma.
Methods
Forty patients with advanced gastric carcinoma were randomly divided into two groups: the research group and the control group with 20 cases in each group. Patients in the research group were given TXT 40 mg/m2 on d1 and d8 plus DDP 30 mg/m2 on days 1, 3. FU 200 mg/m2 was infused continually from day 1–14. Patients in control group received ELF regimen therapy. Etoposide (VP-16) 120 mg/m2, calcium folinate (CF) 200 mg/m2, and FU 500 mg/m2 were given on days 1 and 3. Twenty-eight days were regarded as one cycle. At least two cycles must be completed. The short-term efficacy, adverse reaction, quality of life (QOL), and overall survival (OS) were recorded.
Results
The clinical efficacy could be evaluated in 19 patients of research group and 17 patients in control group. The efficacy of research group was significantly better than that in control group (52.63% vs 17.65%, X 2 = 4.760, P = 0.041). However, the difference was not significant in the frequency of adverse reaction, QOL, median survival time, and OS between the two groups (P > 0.05).
Conclusion
The short-term efficacy of weekly docetaxel and cisplatin plus low dose FU was better than traditional ELF regimen in the treatment of advanced gastric cancer. It had some value for clinical application.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lee J, Park CK, Park JO, et al. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin Cancer Res, 2008, 14: 82–88.
Montero E, Abreu C, Tonino P. Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas. J Cancer Res Clin Oncol, 2008, 134: 193–201.
Lin SZ, Tong HF, You T, et al. Palliative gastrectomy and chemotherapy for stage IV gastric cancer. J Cancer Res Clin Oncol, 2008, 134: 187–192.
Roth, AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol, 2007, 25: 3217–3223.
Chiesa MD, Buti S, Tomasello G, et al. A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer. Tumor, 2007, 93: 244–247.
Maruta F, Ishizone S, Hiraguri M, et al. A clinical study of docetaxel with or without 5’DFUR as a second-line chemotherapy for advanced gastric cancer. Med Oncol, 2007, 24: 71–75.
Neri B, Pantaleo P, Giommoni E, et al. Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study. Br J Cancer, 2007, 96: 1043–1046.
Vellenga E, van Putten WL, van’t Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood, 2008, 111: 537–543.
Kim DY, Joo JK, Ryu SY, et al. Clinicopathological characteristics and prognosis of carcinoma of the gastric cardia. Dig Surg, 2006, 23: 313–318.
Papadakou M, Xydakis E, Bonios M, et al. Adjuvant chemotherapy with cisplatin, etoposide, fluorouracil and leucovorin for gastric carcinoma. J BUON, 2006, 11: 285–289.
Kunisaki C, Akiyama H, Nomura M, et al. Clinicopathological features of gastric carcinoma in younger and middle-aged patients: a comparative study. J Gastrointest Surg, 2006, 10: 1023–1032.
del Casar JM, Corte MD, Alvarer A, et al. Iymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance. J Cancer Res Clin Oncol, 2008, 134: 153–161.
Kivilaakso E. Gastric carcinoma. Scand J Surg, 2006, 95: 215–217.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hou, A., Hu, Y., Zhou, W. et al. Weekly docetaxel, cisplatin and low dose fluorouracil for advanced gastric carcinoma: a randomized clinical trial. Chin. -Ger. J. Clin. Oncol. 8, 516–519 (2009). https://doi.org/10.1007/s10330-009-0107-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-009-0107-6